<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587678</url>
  </required_header>
  <id_info>
    <org_study_id>10387</org_study_id>
    <secondary_id>R01HL075792</secondary_id>
    <nct_id>NCT00587678</nct_id>
  </id_info>
  <brief_title>Comprehensive Magnetic Resonance of Peripheral Arterial Disease</brief_title>
  <official_title>Comprehensive Magnetic Resonance of Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop new ways of imaging fatty blockages in the leg
      arteries to improve upon techniques used now and to develop new ways of understanding how new
      treatments may affect the disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plaque Volume</measure>
    <time_frame>2 years</time_frame>
    <description>SFA plaque volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perfusion Index</measure>
    <time_frame>2 years</time_frame>
    <description>Perfusion index is a MRI measure of calf muscle perfusion indexed to the arterial input. The value is between 0 and 1 with 0 being worst and 1 being best.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphocreatine Recovery Time Constant - the Time it Takes for Phosphocreatine Levels to Recover to Plateau.</measure>
    <time_frame>2 years</time_frame>
    <description>Phosphocreatine recovery time constant is the time it takes for phosphocreatine levels to recover to plateau after the completion of exercise. This ranges from 20 to 1000 seconds. 20-40 seconds is normal and any value over 40 seconds is abnormal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein Cholesterol</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein Cholesterol</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Angiographic Index</measure>
    <time_frame>2 years</time_frame>
    <description>MRA index is a measure of angiographic severity of disease. 0 = no disease and 4 is severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log Treadmill Exercise Time</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute Walk Distance</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V02 - Maximal Oxygen Consumption</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetemibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40mg each night</description>
    <arm_group_label>Randomized</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>10mg daily</description>
    <arm_group_label>Ezetemibe</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin/Ezetimibe</intervention_name>
    <description>40mg/10mg each night</description>
    <arm_group_label>Randomized</arm_group_label>
    <other_name>Vytorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients age 30-85 referred to the vascular imaging laboratory with documented evidence of
        peripheral arterial disease (0.4&lt;ABI&lt;0.9) 96 Normal healthy subjects ages 30-85

        Exclusion Criteria:

        Age&lt;30, &gt;85

        GFR less than 45mL/min based on a serum creatinine drawn within 90 days of the MRI:

        Pregnancy Contraindications to a magnetic resonance examination

          -  Intracranial clips

          -  Implantable pacemaker and defibrillator

          -  Cochlear or intraocular implants

          -  Claustrophobia

          -  Any metallic implant not listed as magnetic resonance compatible in Shellock F.G
             ---Pocket Guide to Magnetic Resonance Procedures and Metallic Objects, Update 2000.
             Lippincott, Williams and Wilkins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher M Kramer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virgina Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Isbell DC, Berr SS, Toledano AY, Epstein FH, Meyer CH, Rogers WJ, Harthun NL, Hagspiel KD, Weltman A, Kramer CM. Delayed calf muscle phosphocreatine recovery after exercise identifies peripheral arterial disease. J Am Coll Cardiol. 2006 Jun 6;47(11):2289-95. Epub 2006 May 15.</citation>
    <PMID>16750698</PMID>
  </reference>
  <reference>
    <citation>Isbell DC, Meyer CH, Rogers WJ, Epstein FH, DiMaria JM, Harthun NL, Wang H, Kramer CM. Reproducibility and reliability of atherosclerotic plaque volume measurements in peripheral arterial disease with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2007;9(1):71-6. Erratum in: J Cardiovasc Magn Reson. 2007;9(3):629.</citation>
    <PMID>17178683</PMID>
  </reference>
  <reference>
    <citation>Isbell DC, Epstein FH, Zhong X, DiMaria JM, Berr SS, Meyer CH, Rogers WJ, Harthun NL, Hagspiel KD, Weltman A, Kramer CM. Calf muscle perfusion at peak exercise in peripheral arterial disease: measurement by first-pass contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2007 May;25(5):1013-20.</citation>
    <PMID>17410566</PMID>
  </reference>
  <reference>
    <citation>Kramer CM. Peripheral arterial disease assessment: wall, perfusion, and spectroscopy. Top Magn Reson Imaging. 2007 Oct;18(5):357-69.</citation>
    <PMID>18025990</PMID>
  </reference>
  <results_reference>
    <citation>West AM, Anderson JD, Meyer CH, Epstein FH, Wang H, Hagspiel KD, Berr SS, Harthun NL, DiMaria JM, Hunter JR, Christopher JM, Chew JD, Winberry GB, Kramer CM. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011 Sep;218(1):156-62. doi: 10.1016/j.atherosclerosis.2011.04.005. Epub 2011 Apr 16.</citation>
    <PMID>21570685</PMID>
  </results_reference>
  <results_reference>
    <citation>West AM, Anderson JD, Epstein FH, Meyer CH, Wang H, Hagspiel KD, Berr SS, Harthun NL, Weltman AL, Dimaria JM, Hunter JR, Christopher JM, Kramer CM. Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. J Am Coll Cardiol. 2011 Aug 30;58(10):1068-76. doi: 10.1016/j.jacc.2011.04.034.</citation>
    <PMID>21867844</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <results_first_submitted>August 2, 2011</results_first_submitted>
  <results_first_submitted_qc>January 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2012</results_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Christopher M. Kramer MD</investigator_full_name>
    <investigator_title>Professor of Radiology and Medicine</investigator_title>
  </responsible_party>
  <keyword>PAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin 40mg</title>
          <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
        </group>
        <group group_id="P2">
          <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
          <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
        </group>
        <group group_id="P3">
          <title>Ezetimibe 10mg</title>
          <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin 40mg</title>
          <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
        </group>
        <group group_id="B2">
          <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
          <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
        </group>
        <group group_id="B3">
          <title>Ezetimibe 10mg</title>
          <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="12"/>
                    <measurement group_id="B2" value="64" spread="9"/>
                    <measurement group_id="B3" value="66" spread="11"/>
                    <measurement group_id="B4" value="63" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194" spread="11"/>
                    <measurement group_id="B2" value="189" spread="10"/>
                    <measurement group_id="B3" value="170" spread="6"/>
                    <measurement group_id="B4" value="182" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low density lipoprotein cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118" spread="10"/>
                    <measurement group_id="B2" value="118" spread="9"/>
                    <measurement group_id="B3" value="100" spread="4"/>
                    <measurement group_id="B4" value="111" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High density lipoprotein cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="4"/>
                    <measurement group_id="B2" value="48" spread="4"/>
                    <measurement group_id="B3" value="42" spread="2"/>
                    <measurement group_id="B4" value="43" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227" spread="47"/>
                    <measurement group_id="B2" value="130" spread="21"/>
                    <measurement group_id="B3" value="157" spread="20"/>
                    <measurement group_id="B4" value="159" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plaque volume</title>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.0" spread="1.5"/>
                    <measurement group_id="B2" value="11.5" spread="1.4"/>
                    <measurement group_id="B3" value="10.0" spread="0.8"/>
                    <measurement group_id="B4" value="10.6" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total vessel volume</title>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.7" spread="2.5"/>
                    <measurement group_id="B2" value="17.5" spread="2.4"/>
                    <measurement group_id="B3" value="15.7" spread="1.2"/>
                    <measurement group_id="B4" value="16.6" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumen volume</title>
          <units>cm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="1.2"/>
                    <measurement group_id="B2" value="5.9" spread="1.1"/>
                    <measurement group_id="B3" value="5.7" spread="0.5"/>
                    <measurement group_id="B4" value="6.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Perfusion index</title>
          <description>First pass contrast-enhanced MRI measure of exercise calf muscle perfusion</description>
          <units>Units on a scale (0 = worst, 1 = best).</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.48" spread="0.18"/>
                    <measurement group_id="B2" value="0.42" spread="0.13"/>
                    <measurement group_id="B3" value="0.51" spread="0.16"/>
                    <measurement group_id="B4" value="0.48" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Phosphocreatine recovery time constant</title>
          <description>Phosphocreatine recovery time constant measured at peak exercise with 31P magnetic resonance spectroscopy. The range is from 20 to 1000 seconds with 20-40 being normal and higher than 40 abnormal.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94" spread="77"/>
                    <measurement group_id="B2" value="104" spread="56"/>
                    <measurement group_id="B3" value="83" spread="62"/>
                    <measurement group_id="B4" value="92" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Magnetic resonance angiographic index</title>
          <description>Index of stenoses based on MR angiogram (0=normal, 4=worst possible)</description>
          <units>units on a scale (0-4). 0 = normal.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.73" spread="0.50"/>
                    <measurement group_id="B2" value="1.10" spread="0.72"/>
                    <measurement group_id="B3" value="0.65" spread="0.62"/>
                    <measurement group_id="B4" value="0.81" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Log of Treadmill Exercise Time</title>
          <units>log of time in seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.08" spread="0.84"/>
                    <measurement group_id="B2" value="5.82" spread="0.67"/>
                    <measurement group_id="B3" value="5.94" spread="0.78"/>
                    <measurement group_id="B4" value="5.95" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6-minute walk distance</title>
          <units>feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1103" spread="407"/>
                    <measurement group_id="B2" value="976" spread="324"/>
                    <measurement group_id="B3" value="1007" spread="435"/>
                    <measurement group_id="B4" value="1024" spread="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>V02 max - maximal oxygen consumption</title>
          <description>Measured during treadmill exercise</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="4.6"/>
                    <measurement group_id="B2" value="12.4" spread="3.2"/>
                    <measurement group_id="B3" value="12.1" spread="3.8"/>
                    <measurement group_id="B4" value="12.8" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plaque Volume</title>
        <description>SFA plaque volume</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Plaque Volume</title>
          <description>SFA plaque volume</description>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="1.4"/>
                    <measurement group_id="O2" value="10.5" spread="1.3"/>
                    <measurement group_id="O3" value="10.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>vs. baseline</p_value_desc>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoprotein Cholesterol</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein Cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="11"/>
                    <measurement group_id="O2" value="68" spread="10"/>
                    <measurement group_id="O3" value="77" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>vs. baseline</p_value_desc>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perfusion Index</title>
        <description>Perfusion index is a MRI measure of calf muscle perfusion indexed to the arterial input. The value is between 0 and 1 with 0 being worst and 1 being best.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Perfusion Index</title>
          <description>Perfusion index is a MRI measure of calf muscle perfusion indexed to the arterial input. The value is between 0 and 1 with 0 being worst and 1 being best.</description>
          <units>Units on a scale (0 = worst, 1 = best)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.19"/>
                    <measurement group_id="O2" value="0.37" spread="0.13"/>
                    <measurement group_id="O3" value="0.54" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phosphocreatine Recovery Time Constant - the Time it Takes for Phosphocreatine Levels to Recover to Plateau.</title>
        <description>Phosphocreatine recovery time constant is the time it takes for phosphocreatine levels to recover to plateau after the completion of exercise. This ranges from 20 to 1000 seconds. 20-40 seconds is normal and any value over 40 seconds is abnormal.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Phosphocreatine Recovery Time Constant - the Time it Takes for Phosphocreatine Levels to Recover to Plateau.</title>
          <description>Phosphocreatine recovery time constant is the time it takes for phosphocreatine levels to recover to plateau after the completion of exercise. This ranges from 20 to 1000 seconds. 20-40 seconds is normal and any value over 40 seconds is abnormal.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="68"/>
                    <measurement group_id="O2" value="73" spread="35"/>
                    <measurement group_id="O3" value="74" spread="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" spread="12"/>
                    <measurement group_id="O2" value="136" spread="12"/>
                    <measurement group_id="O3" value="144" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>vs. baseline</p_value_desc>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein Cholesterol</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein Cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="4"/>
                    <measurement group_id="O2" value="46" spread="3"/>
                    <measurement group_id="O3" value="43" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171" spread="30"/>
                    <measurement group_id="O2" value="119" spread="20"/>
                    <measurement group_id="O3" value="152" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnetic Resonance Angiographic Index</title>
        <description>MRA index is a measure of angiographic severity of disease. 0 = no disease and 4 is severe disease.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Magnetic Resonance Angiographic Index</title>
          <description>MRA index is a measure of angiographic severity of disease. 0 = no disease and 4 is severe disease.</description>
          <units>units on scale (0 = normal, 4 = worst)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.46"/>
                    <measurement group_id="O2" value="1.32" spread="0.86"/>
                    <measurement group_id="O3" value="0.63" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Log Treadmill Exercise Time</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Log Treadmill Exercise Time</title>
          <units>log time in seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" spread="1.08"/>
                    <measurement group_id="O2" value="5.79" spread="0.67"/>
                    <measurement group_id="O3" value="5.78" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.67</p_value>
            <method>linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6-minute Walk Distance</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>6-minute Walk Distance</title>
          <units>ft.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1078" spread="485"/>
                    <measurement group_id="O2" value="1038" spread="248"/>
                    <measurement group_id="O3" value="1099" spread="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>V02 - Maximal Oxygen Consumption</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 40mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
            <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10mg</title>
            <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>V02 - Maximal Oxygen Consumption</title>
          <units>ml/min/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="4.6"/>
                    <measurement group_id="O2" value="12.1" spread="2.9"/>
                    <measurement group_id="O3" value="12.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>Linear repeated measures model</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin 40mg</title>
          <description>Statin naive patients randomized to simvastatin 40mg qhs after baseline studies for 2 years</description>
        </group>
        <group group_id="E2">
          <title>Simvastatin 40mg/Ezetimibe 10 mg</title>
          <description>Statin naive patients randomized to simvastatin 40mg/Ezetimibe 10mg qhs after baseline studies for 2 years</description>
        </group>
        <group group_id="E3">
          <title>Ezetimibe 10mg</title>
          <description>Open label Ezetimibe 10mg daily begun after baseline studies for 2 years</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Christopher Kramer</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-243-0736</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

